280 related articles for article (PubMed ID: 31615279)
1. Preservative-free
Duru Z; Ozsaygili C
Cutan Ocul Toxicol; 2020 Mar; 39(1):21-24. PubMed ID: 31615279
[No Abstract] [Full Text] [Related]
2. Comparisons of efficacy and safety between preserved and preservative-free brimonidine tartrate in glaucoma and ocular hypertension: a parallel-grouped, randomized trial.
Kim KE; Lee CK; Shin J; Kim Y; Rho S
Sci Rep; 2023 Apr; 13(1):5700. PubMed ID: 37029145
[TBL] [Abstract][Full Text] [Related]
3. Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension.
Aptel F; Pfeiffer N; Schmickler S; Clarke J; Lavín-Dapena C; Moreno-Montañés J; Żarnowski T; Csutak A; Jugaste T; Volksone L; Astakhov YS; Coupier L; Nordmann JP; Stalmans I;
J Glaucoma; 2019 Jun; 28(6):498-506. PubMed ID: 31166287
[TBL] [Abstract][Full Text] [Related]
4. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension.
Aptel F; Choudhry R; Stalmans I
Curr Med Res Opin; 2016 Aug; 32(8):1457-63. PubMed ID: 27310103
[TBL] [Abstract][Full Text] [Related]
5. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial.
Kim DW; Shin J; Lee CK; Kim M; Lee S; Rho S
Sci Rep; 2021 Jul; 11(1):14971. PubMed ID: 34294842
[TBL] [Abstract][Full Text] [Related]
7. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
8. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.
Whitson JT; Ochsner KI; Moster MR; Sullivan EK; Andrew RM; Silver LH; Wells DT; James JE; Bosworth CF; Dickerson JE; Landry TA; Bergamini MV;
Ophthalmology; 2006 Aug; 113(8):1333-9. PubMed ID: 16877072
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Intraocular Pressure-Lowering Effect and Safety of Preservative-Free And Preservative-Containing Brimonidine/Timolol Fixed-Combination Ophthalmic Solutions in Patients with Open-Angle Glaucoma.
Kim JM; Kim TW; Park SW; Park HL; Hwang YH; Jeoung JW; Kim CY
Semin Ophthalmol; 2021 Apr; 36(3):103-109. PubMed ID: 33734910
[No Abstract] [Full Text] [Related]
10. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
[TBL] [Abstract][Full Text] [Related]
11. A pharmacoeconomic analysis to determine the relative cost-effectiveness of bimatoprost 0.03% eye drops and brimonidine 0.2% eye drops in patients of primary open-angle glaucoma/ocular hypertension.
Natt NK; Gupta A; Singh G; Singh T
Indian J Ophthalmol; 2014 Dec; 62(12):1136-40. PubMed ID: 25579357
[TBL] [Abstract][Full Text] [Related]
12. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension.
Katz LJ
J Glaucoma; 2002 Apr; 11(2):119-26. PubMed ID: 11912359
[TBL] [Abstract][Full Text] [Related]
13. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications.
Lazreg S; Merad Z; Nouri MT; Garout R; Derdour A; Ghroud N; Kherroubi R; Meziane M; Belkacem S; Ouhadj O; Baudouin C; Tiar M
J Fr Ophtalmol; 2018 Dec; 41(10):945-954. PubMed ID: 30477719
[TBL] [Abstract][Full Text] [Related]
15. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
16. Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension.
Sharpe ED; Day DG; Beischel CJ; Rhodes JS; Stewart JA; Stewart WC
Br J Ophthalmol; 2004 Jul; 88(7):953-6. PubMed ID: 15205246
[TBL] [Abstract][Full Text] [Related]
17. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
Schuman JS
Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Whitson JT; Henry C; Hughes B; Lee DA; Terry S; Fechtner RD
J Glaucoma; 2004 Apr; 13(2):168-73. PubMed ID: 15097265
[TBL] [Abstract][Full Text] [Related]
19. Fixed-combination Bimatoprost/Brimonidine/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil
Belfort R; Paula JS; Lopes Silva MJ; Della Paolera M; Kim T; Chen MY; Goodkin ML
Clin Ther; 2020 Feb; 42(2):263-275. PubMed ID: 32089329
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
DuBiner HB; Mroz M; Shapiro AM; Dirks MS;
Clin Ther; 2001 Dec; 23(12):1969-83. PubMed ID: 11813932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]